Table 4.
Hazard ratios of balloon angioplasty for primary patency compared with nitinol stenting in each subgroup after propensity score matching.
| n (%) | Hazard ratio (95% CI) | |
|---|---|---|
| Patient characteristics | ||
| Age > 80 years | 220 (19) | 1.8 (1.1–3.0)* |
| Female gender | 342 (30) | 1.6 (1.1–2.4)* |
| Nonambulatory | 182 (16) | 0.9 (0.5–1.6) |
| Hypertension | 945 (83) | 1.4 (1.1–1.7)* |
| Dyslipidemia | 575 (50) | 1.1 (0.8–1.5) |
| Diabetes mellitus | 692 (60) | 1.0 (0.8–1.4) |
| Regular dialysis | 328 (29) | 1.3 (0.9–1.9) |
| Current smoking | 295 (26) | 1.1 (0.7–1.6) |
| No use of cilostazol | 701 (61) | 1.1 (0.9–1.5) |
| No use of statin | 720 (63) | 1.2 (0.9–1.5) |
| No use of ACEI or ARB | 565 (49) | 1.5 (1.1–2.0)* |
| CLI | 350 (29) | 1.3 (0.9–1.9) |
| Lesion characteristics | ||
| TASC II C/D | 197 (17) | 1.4 (0.9–2.2) |
| Lesion length | ||
| >150 mm | 138 (12) | 2.1 (1.1–3.9)* |
| >100 mm | 246 (22) | 1.1 (0.7–1.7) |
| Reference diameter | ||
| <6 mm | 805 (70) | 1.2 (0.9–1.5) |
| <5 mm | 337 (29) | 1.2 (0.8–1.8) |
| Calcification | 672 (59) | 1.3 (1.0–1.7) |
| CTO | 393 (34) | 1.3 (0.9–1.8) |
| Poor run-off | 479 (42) | 1.3 (1.0–1.9) |
CI: confidence interval; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CLI: critical limb ischemia; TASC: Trans-Atlantic Inter-Society Consensus; CTO: chronic total occlusion.
*
p < 0.05.